**Friday 9 Feb 2017**

15.30-16.00: **Reception**

16.00-16.15: **Welcome and meeting objectives**

by local faculty and introduction of local faculty members

16.15-18.00: **General session 1: Diagnosis and Multimodality Treatment of Localized Disease**

Recorded sessions from ASCO GU San Francisco – selectie uit de volgende sessies:

**Christopher J. Kane, MD—Chair**  
University of California, San Diego  
  
**Thomas J. Pugh, MD—Chair**  
University of Colorado  
  
**Daniel W. Lin, MD**  
University of Washington  
*Welcome*  
  
*Case-Based Debate: Magnetic Resonance and Magnetic Resonance-Directed Biopsy: Where Is the Field Moving?*  
  
**Christopher J. Kane, MD**  
University of California, San Diego  
*Moderator*  
  
**TBD**  
*Radiologist*  
  
**Caroline Moore, MD, FRCS(Urol)**  
University College London  
*Urologist*  
  
**Mary-Ellen Taplin, MD**  
Dana-Farber Cancer Institute  
*Newly-Diagnosed High-Risk Disease Treatment: Summarizing Neoadjuvant Trials*  
  
**Alberto Briganti, MD, PhD**  
Vita-Salute San Raffaele University, Urological Research Institute, IRCCS Ospedale San Raffaele  
*Adjuvant Radiotherapy and Chemotherapy in Node-Positive Disease*  
  
*Case-Based Debate: Treating High-Risk Patients After Prostatectomy: Adjuvant Therapy Versus Early-Salvage Therapy*  
  
**TBD**  
*Moderator*  
  
**Christopher L. Amling, MD**  
Oregon Health & Science University  
*Adjuvant Advocate*  
  
**William U. Shipley, MD, FACR**  
Massachusetts General Hospital, Harvard Medical School  
*Early-Salvage Advocate*  
  
*Panel Question and Answer*

18.00-18.20: **Break**

18.20-19.45: **General Session 2: Emerging Diagnostics and Therapies in Advanced Prostate Cancer**

Recorded sessions from ASCO GU San Francisco – Selectie uit de volgende sessies:

**William L. Dahut, MD—Chair**  
National Cancer Institute  
  
**Himisha Beltran, MD—Chair**  
Weill Cornell Medical College  
  
**TBD**  
*Emerging Immunotherapy Strategies for Castrate Resistant Prostate Cancer*  
  
**Felix Feng, MD**  
University of California, San Francisco  
*Management of Oligometastatic Prostate Cancer From Imaging to Therapy*  
  
**Kim N. Chi, MD, FRCPC**  
British Columbia Cancer Agency  
*Incorporating Genomics Into the Management of Systemic Therapy: Advances and Practicality*  
  
**Joe M. O'Sullivan, MD, FRCR**  
Queen's University Belfast  
*Molecular Therapies in Bone Metastases*  
  
*Panel Question and Answer*

19.45-20.00: Preparation of questions for live session

20.00-21.00: **Diner (first part)**

21.00-21.30: **Live connection with San Francisco**

***Topics for Q&A: oligomets & genomics + what does it mean for current daily practice?***

**Andre Bergman (NKI-AVL)**

**Felix Feng (University of California, San Fransisco)**

**Kim N. Chi (British Columbia Cancer Agency**

21.30: Wrap up and day 1 closure

21.40: **Dessert**

**Saturday 10 Feb 2017**

8.15-8.30: **Wrap up Friday program and preview of Saturday program**

by local faculty

8.30-9.30: **General Session 3: Moderated Debates on Controversial Topics in Prostate Cancer**

Recorded sessions from ASCO GU San Francisco – Selectie uit de volgende sessies:

**Prostate Cancer: Keynote Lecture**  
**TBD**  
Germline and Somatic Mutational Landscape in Prostate Cancer: State of Knowledge and Implications for Practice

**Justin E. Bekelman, MD—Chair**  
Perelman School of Medicine at the University of Pennsylvania  
  
**Francesco Montorsi, MD—Chair**  
Universita Vita Salute San Raffaele  
  
Case-Based Debate: Is There Evidence for Local Treatment in Patients with Newly Diagnosed Metastatic Disease?  
  
**Elisabeth I. Heath, M.D.**  
Barbara Ann Karmanos Cancer Institute, Wayne State University  
Moderator  
  
**Mack Roach III, MD, FASCO**  
University of California, San Francisco  
Advocate  
  
**Adam Dicker, MD, PhD**  
Sidney Kimmel Cancer Center  
Skeptic  
  
Case-Based Debate: Abiraterone Versus Docetaxel  
  
**Nicholas J. Van As, FRCR**  
The Royal Marsden NHS Foundation Trust  
Moderator  
  
**Karim Fizazi, MD, PhD**  
Gustave Roussy, University of Paris Sud  
Abiraterone Advocate  
  
**Christopher Sweeney, MBBS**  
Dana-Farber Cancer Institute  
Docetaxel Advocate  
  
Panel Question and Answer

9.30-9.45: Case discussion (own casus of faculty)

9.45-10.15: Selected poster sessions (Poster presenters interviews)

10.15-10.30: **Break**

10.30-12.00: **General Session 4: Current and Future Directions of Muscle-Invasive Bladder Cancer**

Recorded sessions from ASCO GU San Francisco- selectie uit de volgende sessies:

**Jeanny B. Aragon-Ching, MD, FACP—Chair**  
Inova Schar Cancer Institute  
  
**Nicholas J. Van As, FRCR—Chair**  
The Royal Marsden NHS Foundation Trust  
  
**Jeffrey M. Holzbeierlein, MD, FACS**  
 University of Kansas Health System  
Welcome and Lessons Learned From New Guidelines and How They Have Changed Management of Muscle-Invasive Bladder Cancer  
  
**Peter C. Black, MD**  
University of British Columbia  
Selective Versus Nonselective Use of Neoadjuvant Chemotherapy: Use of Molecular Markers for Identifying Patients and Therapies  
  
**Peter Hoskin, MD, FRCP, FRCR**  
Mount Vernon Cancer Centre  
Use of Molecular Markers in Bladder Preservation Therapy  
  
**Abhishek A. Solanki, MD, MS**  
Loyola University Chicago  
Role of Immunotherapy in Patients Undergoing Radiation Therapy for Bladder Cancer  
  
Panel Question and Answer

12.00-12.15: Case discussion (own casus of faculty)

12.15-13.00: **Lunch**

13.00-14.30: **General Session 5: Multimodality Approach to Locally Advanced Bladder Cancer (ARS)**

Recorded sessions from ASCO GU San Francisco- selectie uit de volgende sessies:

**Ananya Choudhury, MA, PhD, MRCP, FRCR—Chair**  
The Christie NHS Foundation Trust and University of Manchester  
  
**Yair Lotan, MD—Chair**  
The University of Texas Southwestern Medical Center  
  
Case Panel Discussion  
  
**Alison J. Birtle, MRCP, FRCR, MD**  
Lancashire Teaching Hospitals NHS Trust  
Radiation Oncologist  
  
**Alfred Witjes, MD, PhD**  
Radboud University Nijmegen Medical Centre  
Urologist  
  
**Dean F. Bajorin, MD, FACP, FASCO**  
Memorial Sloan-Kettering Cancer Center  
Medical Oncologist  
  
Panel Question and Answer

14.30-14.45: **Break**

14.45-15.30: **Recorded session with questions by Dutch participants**

**Alison J. Birtle (Lancashire Teaching Hospitals NHS Trust)**

**Dean F. Bajorin (Memorial Sloan-Kettering Cancer Center)**

**Fred Witjes (Radboud University Nijmegen Medical Centre) (moderator /interviewer)**

topic: bladder preservation and modalities including immunotherapy

15.30-16.00: **Meeting close & wrap up**

By local faculty